Melanoma

Citing toxicities and lack of efficacy, some are calling for caution when treating older patients with melanoma with immune checkpoint inhibitors.

The TIL therapy OBX-115 ‘may have the potential to address’ an unmet need among patients with metastatic or locally advanced melanoma.

Perioperative treatment with BRAF and MEK inhibitors was found to benefit some patients with stage 3 and 4 melanoma, according to a recent study.

Following promising European trial results, a new peptide vaccine for melanoma is being studied in America, with results expected next year.

With many groundbreaking cancer therapies on the horizon, it's also time to focus on up and coming cancer vaccines.

Are cancer vaccines the new frontier in oncology? Experts and patients weigh in from the front lines.

Learning that I had cancer — melanoma and renal cell carcinoma — made me feel like I lost something, but I keep looking ahead.

Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.

When my wife was diagnosed with stage 3B melanoma, we decided to openly speak about our fears.

A type of therapy that involves “liberating” T cells from a suppressive tumor environment showed promise in the treatment of patients with uveal melanoma.

An expert explained the importance of patient choice in treatment decisions for high-risk, resectable melanoma, based on their own treatment goals.

Since January 2024, the Food and Drug Administration has approved several treatments and combinations for solid tumors.

A vaccine developer discusses a cancer vaccine that has been shown to potentially boost long-term overall postsurgical survival.

Melanoma survivors may have an increased risk of recurrence, which may heighten fear and worry, but “it’s OK and normal to be worried,” a doctor said.

From Fortnight player, “Ninja” announcing his melanoma diagnosis to an LSU quarterback sporting the name of his teammate with brain cancer, here’s what’s going on in the oncology space this week.

From Oliva Munn and Christine Brinkley discussing their cancer to Donnie Iris returning to the stage after his experience with the disease, here is what’s happening in the oncology space this week.

Treatment with Amtagvi, a TIL therapy recently approved for advanced melanoma, includes a three-week hospital stay upfront, but may lead to years of monitoring without more treatment needed, an expert explained.

Personalized cancer vaccines are on the horizon and could be available for some patient populations as soon as next year, one expert said.

Moderna and Merck have initiated V940-001, a phase 3 study evaluating vaccine mRNA-4157 and anti-PD-1 therapy Keytruda as postsurgical treatment for stage 2B to 4 melanoma.

From the Duchess of York receiving a skin cancer diagnosis to Selena Gomez contacting a fan with stage 4 disease, here’s what is happening in the oncology space this week.

Vd1-gd T cells, a rare type of immune cell, have been found to potentially predict how likely it is that certain patients with advanced skin cancer will be responsive to treatment via immunotherapy, according to recently published research.

As ‘Big Bang Theory’ star Kate Micucci announced that she is cancer-free and ‘Married at First Sight’ dating coach Mel Schilling announced her cancer diagnosis, here is what’s happening in the oncology space this week.

Patients with advanced-stage melanoma continue to experience reduced risk of recurrence or death following treatment with a combination of mRNA vaccine mRNA-4157 (V940) and Keytruda, an anti-PD-1 therapy, according to recent study findings.

In honor of National Family Caregiver’s Month, CURE® highlights some of the most important news in 2023.

An expert reflects on the recent FDA approval of adjuvant Opdivo for patients with stage 2B or 2C melanoma.

A phase 2 study evaluated meaningful activity from lifileucel for patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors.

A diagnosis of a rare internal form of melanoma left J.B. Ward and her care team in “a whirlwind of confusion,” but she pushed for aggressive forms of treatment.